In a report released on May 23, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Zymeworks (ZYME – Research Report), with a price target of $19.00. The company’s shares closed yesterday at $8.80.
According to TipRanks, Willey is a 5-star analyst with an average return of 13.8% and a 46.38% success rate. Willey covers the Healthcare sector, focusing on stocks such as Atreca, Exelixis, and Zymeworks.
Currently, the analyst consensus on Zymeworks is a Moderate Buy with an average price target of $12.88, which is a 46.36% upside from current levels. In a report released on May 18, Citi also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
Based on Zymeworks’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $5.44 million and a GAAP net loss of $64.62 million. In comparison, last year the company earned a revenue of $1.77 million and had a GAAP net loss of $67.52 million
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ZYME in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Read More on ZYME:
- 3 Best Stocks to Buy Now, 5/19/2023, According to Top Analysts
- Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
- Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
- Is ZYME a Buy, Before Earnings?
- Zymeworks Announces Participation in Upcoming Investor Conferences
